» Articles » PMID: 10411588

Proteinase-activated Receptor 2 (PAR(2)): Development of a Ligand-binding Assay Correlating with Activation of PAR(2) by PAR(1)- and PAR(2)-derived Peptide Ligands

Overview
Specialty Pharmacology
Date 1999 Jul 20
PMID 10411588
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

A cloned rat proteinase-activated receptor (PAR)(2)-expressing cell line (KNRK-rPAR(2)) was used to study the structure-activity relationships (elevated intracellular Ca(2+)) for a series of: 1) PAR(1)-derived receptor-activating ligands (PAR(1)-APs) [SFLLR (P5), SFLLR-NH(2) (P5-NH(2)), SFLLRNP (P7), SFLLRNP-NH(2) (P7-NH(2)), and TFLLR-NH(2) (TF-NH(2))] and 2) PAR(2)-derived-activating-peptides (PAR(2)-APs) [SLIGRL-NH(2) (SL-NH(2)), SLIGR-NH(2) (GR-NH(2)), and SLIGKV-NH(2) (KV-NH(2))]. The activities of the PAR-APs were compared with the PAR(2)-AP analog trans-cinnamoyl-Leu-Ile-Gly-Arg-Leu-Orn-NH(2) tc-NH(2)), which as a [(3)H]propionyl derivative ([(3)H]propionyl-tc-NH(2)) was used to develop a radioligand-binding assay for PAR(2). The relative potencies of the PAR-APs in the Ca(2+)-signaling assay were tc-NH(2) = SL-NH(2) > KV-NH(2) congruent with P5-NH(2) > GR-NH(2) > P7-NH(2) > P7 > P5 > TF-NH(2). The reverse sequence PAR-APs, LSIGRL-NH(2) (LS-NH(2)), LRGILS-NH(2) (LR-NH(2)), FSLLRY-NH(2) (FSY-NH(2)), and FSLLR-NH(2) (FS-NH(2)), as well as the Xenopus PAR(1)-AP TFRIFD-NH(2), were inactive. The relative biological potencies of the peptides were in accord with their ability to compete for the binding of [(3)H]propionyl-tc-NH(2) (tc-NH(2) = SL-NH(2) > GR-NH(2) congruent with P5-NH(2) > P5) to KNRK-rPAR(2) cells, whereas inactive peptides (FS-NH(2); LR-NH(2)) showed no appreciable binding competition. Our data therefore validate a ligand-binding assay for the use in studies of PAR(2) and indicate that the relative biological potencies of the PAR(1)-APs for activating rat PAR(2) parallel their ability to activate human PAR(1). The relative receptor-binding activities of the PAR-APs, although in general agreement with their relative biological activities, point to differences in the intrinsic receptor-activating activities between the several PAR-APs. The binding assay we have developed should prove of use for the further study of PAR(2)-ligand interactions.

Citing Articles

Protease Activated Receptors and Arthritis.

Lucena F, McDougall J Int J Mol Sci. 2021; 22(17).

PMID: 34502257 PMC: 8430764. DOI: 10.3390/ijms22179352.


High Affinity Fluorescent Probe for Proteinase-Activated Receptor 2 (PAR2).

LeSarge J, Thibeault P, Milne M, Ramachandran R, Luyt L ACS Med Chem Lett. 2019; 10(7):1045-1050.

PMID: 31312406 PMC: 6627725. DOI: 10.1021/acsmedchemlett.9b00094.


Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases.

Heuberger D, Schuepbach R Thromb J. 2019; 17:4.

PMID: 30976204 PMC: 6440139. DOI: 10.1186/s12959-019-0194-8.


Protease activated receptors in cardiovascular function and disease.

Barnes J, Singh S, Gomes A Mol Cell Biochem. 2016; 263(1):227-39.

PMID: 27520681 DOI: 10.1023/B:MCBI.0000041864.14092.5b.


Proteinases, their receptors and inflammatory signalling: the Oxford South Parks Road connection.

Hollenberg M Br J Pharmacol. 2014; 172(13):3196-211.

PMID: 25521749 PMC: 4500360. DOI: 10.1111/bph.13041.